Peptide analogues of the class A amphipathic helixes from exchangeable apolipoproteins mimic apolipoprotein (apo) A-I in a number of ways, including the ability to activate the enzyme lecithin: cholesterol acyltransferase, to associate with high density lipoproteins (HDLs), and to form HDL-like particles in the presence of lipids. This study investigated the metabolic properties of several of these peptide analogues in the rat Peptide analogues studied were 18A (referred to as L-18A to differentiate it from D-18A, and which mimics apolipoprotein amphipathic helical domains in its charge distribution), 37pA (a dimer of two 18A monomers separated by a proline), 18R (with reversed charge distribution compared with 18A), and D-18A (identical in amino acid sequence to 18A but synthesized from D-amino acids). Peptides were radiolabeled with l2S l. In addition, metabolism of rat and human 1Z5 I-apo A-I and human 14 C-apo A-I was studied; no significant differences in clearance of these preparations were seen. Clearance data were fitted to multiexponential equations to give half-times of clearance; biexponential equations consistently provided the best nonlinear least-squares curve fit The order of relative lipid affinity determined in vitro was 37pA>apo A-I>D-18A=L-18A>18R. Half-times of clearance were in the same approximate rank order: 37pA, 6.9±3J hours (mean±SD); apo A-I, 6.9±1.8 hours; D-18A, 4.0 ±1.0 hours; L-18A, 4.6 ±1.6 hours; and 18R, 0.9±0.1 hour. Rats injected with L-18A had five times more radioactivity in the urine than did rats injected with D-18A. All urine radioactivity was present as free I23 I in rats injected with L-18A or apo A-I but was present as intact peptide (with no free II5 I) in rats injected with D-18A. The majority of radioactivity in L-and D-18A-injected rats was associated with the thyroid gland (in the case of L-18A), the liver, and the kidney. In summary, the rates of clearance of amphipathic helical peptides from the plasma compartment in rats decrease as the affinities of the peptides for lipoprotein surfaces increase. Stereoconformation did not affect the rate of clearance of peptide analogues. Although a significant proportion of radioactivity in L and D-18A-injected animals was associated with the kidney, excretion of intact peptides in the urine did not appear to be a major route of clearance. ( 
Peptide analogues of the class A amphipathic helixes from exchangeable apolipoproteins mimic apolipoprotein (apo) A-I in a number of ways, including the ability to activate the enzyme lecithin: cholesterol acyltransferase, to associate with high density lipoproteins (HDLs), and to form HDL-like particles in the presence of lipids. This study investigated the metabolic properties of several of these peptide analogues in the rat Peptide analogues studied were 18A (referred to as L-18A to differentiate it from D-18A, and which mimics apolipoprotein amphipathic helical domains in its charge distribution), 37pA (a dimer of two 18A monomers separated by a proline), 18R (with reversed charge distribution compared with 18A), and D-18A (identical in amino acid sequence to 18A but synthesized from D-amino acids). Peptides were radiolabeled with l2S l. In addition, metabolism of rat and human 1Z5 I-apo A-I and human 14 C-apo A-I was studied; no significant differences in clearance of these preparations were seen. Clearance data were fitted to multiexponential equations to give half-times of clearance; biexponential equations consistently provided the best nonlinear least-squares curve fit The order of relative lipid affinity determined in vitro was 37pA>apo A-I>D-18A=L-18A>18R. Half-times of clearance were in the same approximate rank order: 37pA, 6.9±3J hours (mean±SD); apo A-I, 6.9±1.8 hours; D-18A, 4.0 ±1.0 hours; L-18A, 4.6 ±1.6 hours; and 18R, 0.9±0.1 hour. Rats injected with L-18A had five times more radioactivity in the urine than did rats injected with D-18A. All urine radioactivity was present as free I23 I in rats injected with L-18A or apo A-I but was present as intact peptide (with no free II5 I) in rats injected with D-18A. The majority of radioactivity in L-and D-18A-injected rats was associated with the thyroid gland (in the case of L-18A), the liver, and the kidney. In summary, the rates of clearance of amphipathic helical peptides from the plasma compartment in rats decrease as the affinities of the peptides for lipoprotein surfaces increase. Stereoconformation did not affect the rate of clearance of peptide analogues. Although a significant proportion of radioactivity in L and D-18A-injected animals was associated with the kidney, excretion of intact peptides in the urine did not appear to be a major route of clearance. ( has been shown to be directly related to levels of total plasma and low density lipoprotein (LDL) cholesterol and to be inversely related to levels of high density lipoprotein (HDL). In addition, high plasma levels of HDL and apolipoprotein (apo) A-I, the major apolipoprotein component of HDL, are a com- 18A-P-18A 49 53 DMPC, dimyristoylphosphatidylcholine. Data are from the present study and References 4 and 5. L-18A and D-18A have identical sequences, but D-18A was synthesized from D-amino acids. Percent a-helicity was calculated from circular dichroism data as described in "Methods." faces and the negative charges occurring along the center of the polar face. 34 Our laboratory has been designing and studying peptide analogues of apolipoproteins to understand both the in vitro and in vivo properties of apolipoproteins. 5 These analogues mimic apo A-I in their ability to activate the enzyme lecithin: cholesterol acyltransferase, associate with HDL with varying affinities, displace apo A-I from HDL, and form HDL-like particles in the presence of lipid. 5 The present studies are aimed at understanding the metabolic properties of synthetic peptide analogues and correlating these properties with physical chemical properties to design analogues that can promote the formation of HDL-like lipoprotein particles in vivo.
Peptide L-18A is a prototypical peptide analogue in which the charged residues are arranged to mimic the amphipathic helical domains present in class A exchangeable apolipoproteins in terms of hydrophobic moment 6 and charge distribution. 4 The positively charged residues are localized at the polar-nonpolar interface, and the negatively charged residues are at the center of the polar face. The primary sequence (Table  1) has no homologies to any of the naturally occurring peptides and proteins. Analogue 37pA, a dimer of L-18A with a proline residue between the two monomer units, mimics the tandem-repetitive 22-mer amphipathic hehcal repeating units that are characteristic of apos A-I, A-IV, and E. 7 -8 Peptide 18R contains the same amino acid residues as L-18A, but their arrangement has been altered (Table 1) so that the positive charges are in the middle of the polar face of the helix and the negative charges are at the interface between the polar and nonpolar regions. This peptide has a reduced lipid affinity compared with that of other peptide analogues. 5 An amphipathic peptide made up of D-amino acids would be expected to produce a peptide analogue that should have similar lipid affinity to its L-isomer but would not be susceptible to in vivo proteolytic degradation. However, the D-peptide analogue may have different turnover characteristics because it may be recognized by the body as a foreign material. Thus, studies of the turnover of HDL containing r>peptide analogues are required to provide important information regarding their biological activity.
The current study was intended to investigate the characteristics of peptide analogue turnover in an animal model, the rat. The rates of peptide turnover were correlated with their relative lipid affinities. In addition, the turnovers of rat and human apo A-I were determined to data.
provide a basis for comparison of the peptide
Methods

Apo A-I Isolation
Blood from human donors or rats was collected into EDTA, and plasma was separated by centrifugation. HDL was separated from the plasma by density gradient ultracentrifugation 9 and was delipidated with 2:1 (vol/vol) chloroform/methanol. Apo A-I was preparativery isolated by high-performance liquid chromatography (HPLC) 10 ; purity was confirmed by analytical HPLC and sodium dodecyl sulfate-poryacrylamide gel electrophoresis.
Synthetic Peptides
Peptides were synthesized by the solid-phase synthesis procedure previously described 11 by using L-amino acids or D-amino acids (Advanced Chemtech, Louisville, Ky.). The solid-state peptide synthesis procedure has been shown not to produce racemization of amino acid residues. 12 Peptides used in this study were 37pA (18A-P-18A), 18R, and two forms of 18A; L-18A was synthesized by using L-amino acids, whereas D-18A was synthesized by using D-amino acids. The primary sequences of the peptides are shown in Table 1 .
Surface-Tension Measurements (Relative Lipid Affinity)
Surface-pressure measurements were made with the Wilhelmy plate technique by using egg phosphatidylcholine that was spread as a monolayer to which the peptide adsorbed. 13 Initial surface pressure was 10 dynes/cm; the peptide or apo A-I concentration was 1 x 10" 4 g/dl in phosphate buffer (pH 7.0) at 25°C. An increase in surface pressure is the result of penetration of peptide molecules into the monolayer and therefore is a reflection of the affinity of the peptide for the lipid-water interface.
Circular Dichroism Measurements
Circular dichroism (CD) spectra were used to compare secondary structural features of D-18A and L-18A peptides in aqueous solution and in the presence of lipids.
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- 14 Peptides were dissolved in phosphate-buffered saline (10 mM KH 2 PO 4 , 150 mM NaCl, pH 7.4). Peptide concentrations were determined by measuring the optical density at 280 am in 4 M guanidine hydrochloride solution. Peptide-lipid complexes were formed by adding dimyristoylphosphatidylcholine (DMPC) or dimyristoylphosphatidylglycerol (DMPG) in chloroform/methanol solvent to a test tube, evaporating the solvent to form a film of lipid, adding the phosphatebuffered saline, vortexing the mixture to form multilamellar vesicles, and then adding the peptide. The final peptide solutions contained 50 fig peptide/ml, with increasing molar proportions of DMPC or DMPG or an increasing percentage of trifluoroethanol. Complexes were not separated from free peptide or lipid before analysis. The CD spectra were taken with a JASCO-500 spectropolarimeter coupled to a DPN-500 integrator; samples were measured in 1-mm cells. Eight or 16 scans were averaged and corrected for the baseline. The corrected data were used to calculate the mean residue ellipticities; a-helicity was calculated as previously described.
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Turnover of Peptides and Apo A-I in Rats
Human apo A-I, rat apo A-I, and peptide analogues were radioiodinated by the iodine monochloride method 16 and were dialyzed extensively against 0.9% NaCl solution. Human M C-apo A-I was prepared by U Cmethyl exchange. 17 Male Sprague-Dawley rats weighing between 200 and 250 g were anesthetized with xylazine/ ketamine, and 0.2 ml apo A-I or peptide analogue solution (approximately 3xlO 6 cpm) was injected into the saphenous vein. At 2 minutes after injection, 1 ml blood was drawn from the contralateral femoral vein into a syringe containing EDTA to a final concentration of 5 mmol/1 EDTA. Three to five animals were killed by exsanguination from the abdominal aorta into EDTA at each subsequent time point as noted in the figures. Urine was collected from each animal at the final time point. All procedures using animals were previously approved by the institutional animal care and use committee.
Plasma was separated from blood by centrifugation within 1 hour after collection, and radioactivity was determined in each sample by using a Packard gamma counter. Samples were stored at 4°C until chromatographic separation of lipoproteins was done as described below.
Radioactivity in each sample was compared with the radioactivity in the 2-minute sample from the same animal and was expressed as a percentage of the 2-minute radioactivity (%2' cpm in the equation below). Clearance curves of radioactivity were fitted to multiexponential equations to determine the rate of the rapid phase and the slow phase of clearance. Fitting was done using the RSTRIP program (Micromath Scientific Software, Salt Lake City, Utah). All data points, rather than averages at each time point, were used in the fitting. In all cases, biexponential equations provided the most appropriate nonlinear least-squares curve fit. The form of the biexponential equation is %2' cpm=A 1 e~* lt +A 2 e~* 2t where t is time after injection, A, and A 2 are the relative amounts of slowly and rapidly removed material, respectively, and ki and k 2 are the respective decay constants. The standard deviation of each parameter was provided by the program and was used to calculate standard deviations of the half-time of clearance shown in Table 3 .
Chromatographic Separation of Lipoproteins
Lipoproteins from rat plasma samples were separated by fast protein liquid chromatography by using a modification of the low-pressure chromatography procedure of Rudel et al. 18 Up to 1 ml plasma was injected into a lxl20-cm column (Kontes) packed with Superose 6-B (Pharmacia/LKB, Piscataway, N J.) that had been equilibrated with running buffer (0.9% NaCl, 100 mmol/1 KH 2 PO 4 , 2 mmol/1 EDTA, 0.1% NaN 3 , pH 7.4). Fractions were eluted with running buffer at a flow rate of 1 ml/min and were collected. Radioactivity in each fraction was measured. Radioactivity in each lipoprotein peak in the free protein/peptide and the free iodide 'Values represent increases in surface pressure (hir^) within ±1 dyne/cm. An egg phosphatidylcholine monolayer was spread at the air-water interface at an initial surface pressure of 10 dynes/cm. The peptide or apo A-I concentration was 1 x 10" 4 g/dl in phosphate buffer (pH 7.0) at 25°C; this concentration gave maximal adsorption of peptide or protein.
regions was determined by computer-assisted integration. Elution times of HDL, free protein, or free peptide were determined by chromatography of lipoproteins isolated by ultracentrifugation or by chromatography of isolated apo A-I or peptide.
Radioactivity in urine was analyzed by reverse-phase HPLC. Urine was applied to a C-4 silica-gel column (Vydac) equilibrated with 5% acetonitrile and 0.1% trifluoroacetic acid in water. Samples were eluted with a 1.5%/min acetonitrile gradient (containing 0.1% trifluoroacetic acid) at a flow rate of 1.2 ml/min, and 1-minute fractions were collected for measurement of radioactivity by gamma counting. Free 125 I eluted very early (5 minutes) into the gradient, whereas intact peptide eluted 40 minutes into the gradient. Peptide and free 125 I elution times were determined by injection of standard material.
Organ Distribution of L-and D-18A
Organ distribution of L-and D-18A was determined by injecting 125 I-peptides (approximately 4xlO 6 cpm) into the saphenous vein. Six animals were used for each peptide, three males and three females. A blood sample was taken from the contralateral femoral vein 2 minutes after injection. At 3 days after injection, the animals were killed and the organs harvested. At that point, <0.001% of the injected radioactivity was expected to be present in the blood, as based on the clearance rates described here; this was confirmed by measurement of blood radioactivity. Whole organs were counted in most cases; in the case of the liver, lung, abdominal muscle, abdominal fat, prostate gland, and semen, representative samples of the available material were used for determination of radioactivity. Radioactivity in the entire organ was calculated for the liver and lung by correcting for the weight of the counted material compared with the weight of the whole organ. In the case of paired organs, radioactivity in both organs was determined and added together.
Results
Peptide Adsorption Measurements (Relative Lipid Affinities)
The relative lipid affinities of apo A-I and the various peptides were determined by measuring increases in surface pressure; these data are presented in prior data obtained for certain peptides. 1119 It is noteworthy that the L-and D-18A peptides exhibited identical lipid affinities.
Circular Dichroism of D-18A Versus L-18A Peptide
CD was used to measure the chirality and a-helicity of L-18A and D-18A peptides. CD spectra showed that the conformations of the two peptides were equal but opposite in all of the peptide-to-lipid ratios with two different lipids, DMPC or DMPG, and in trifluoroethanol, an o-helix-inducing solvent. The CD results of the two peptides were essentially mirror images, thus confirming the opposite configurations of the two peptides. Representative CD spectra are presented in Figure 1 ; spectra for the two peptides complexed with other lipids at various stoichiometries always showed the mirrorimage effect.
As reported previously, 11 37pA had a high a-helicity in aqueous buffer compared with 18A. The change in a-helicity in the presence of lipid was marginal. The a-helicity of 18A increased up to a lipid-to-peptide molar ratio of 20, and then it remained constant. 18R did not have an appreciable change in a-helicity at different peptide-to-lipid ratios.
Protein and Peptide Analogue Turnover
Comparison of rat and human
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I-apo A-I and human 14 C-apo A-I. As shown below, turnover of peptide analogues in rats was compared with turnover of human apo A-I. To determine if the difference in amino acid sequence affected clearance of apo A-I, 125 I-rat apo A-I clearance was compared with 125 I-human apo A-I clearance in rats. Rats were injected with 125 I-apo A-I isolated from either rats or humans, and blood samples were collected at intervals up to 48 hours thereafter. As shown in Figure 2 , the clearance of the two apolipoproteins was essentially identical.
To determine if radioiodination affected the turnover of apo A-I, rats were injected with u C-human apo A-I, and blood samples were collected at intervals up to 48 hours; data are shown in Figure 2 .
Plasma samples were separated by size-exclusion column chromatography; all radioactivity was in the HDL or free-iodine fractions in plasma from rats in- 
CM
Turnover rates of apolipoprotein A-I (apo A-I) or peptide analogues were determined as depicted in Figure 3 . Half-times of clearance of radioactivity (ti/ 2 ) were determined by fitting clearance data to a biexponential decay curve.
erage half-times of clearance of radioactivity from the fast and slow components for each protein or peptide were derived from the fitted biexponential equations and are shown in Table 3 . Both apo A-I and 37pA had a slow-component half-time of approximately 7 hours, which is comparable to the half-times for apo A-I in rats as reported by other investigators. 20 To determine if initial binding of apo A-I to HDL affected the half-time, a preparation of 125 I-apo A-I was divided, and half was preincubated with whole rat plasma for 15 minutes at room temperature while the other half was incubated with a similar volume of 0.9% NaCl solution before injection into rats. As shown in Figure 4 , clearance of plasma-and saline-incubated apo A-I was identical.
Lipoproteins, free protein or peptide, and free 125 I were chromatographicalry separated at each time point during each experiment. A representative separation for 18R peptide is shown in Figure 5 . Distributions of radioactivity are shown in Table 4 . Virtually all of the apo A-I, L-18A peptide, and 37pA peptide was associated with HDL within 2 minutes after injection, and the proportion of radioactivity across the chromatographic separation did not change over the course of the experiment, except that the proportion of radioactivity in free 125 I increased with time. The 18R analogue had significantly more radioactivity in the free peptide region than did apo A-I or the other peptides. D-18A peptide had a distribution of radiolabel similar to L-18A peptide, except that the proportion of free 125 I did not increase (and in fact decreased) with time.
Urine was collected from rats injected with L-18A and D-18A at the time of final blood collection (60, 80, 120, or 240 minutes), and radioactivity was measured. At 80, 120, and 240 minutes, urine from rats injected with L-18A contained substantially more radioactivity than Blood samples were taken at various time points after injection of ^I-labeled apolipoprotein A-I (apo A-I) or peptide analogues, and plasma was collected by centrifugation. Samples were added to a lxl20-cm Superose 6-B column to separate high density lipoprotein (HDL) from free peptide or free ™I. Peak areas were determined by computer-assisted integration. Percent distribution was determined by dividing radioactivity in each peak by total radioactivity across the column; variable baselines or the presence of radioactivity in nonprotein, peptide, or 123 I areas caused areas to not add up to 100% in some cases. Data represent mean±SEM. ND, not determined.
Organ Distribution of L-and D-18A
Organ distributions of 125 I-L-and D-18A 3 days after injection of labeled peptide are presented in Table 5 prostate gland, and semen were measured as counts per minute per gram tissue weight, and other organs were expressed as counts per minute per total organ (or counts per minute per both organs in tie case of paired organs); thus, recovered radioactivity is an underestimation of the radioactivity present in the whole animal. Of the recovered radioactivity, 94.0±0.4% of the L-18A and 034±0.07% of the D-18A radioactivity were recovered in the thyroid gland. Inclusion of the radioactivity recovered in the thyroid gland would make comparisons between Land D-18A tissue distribution difficult, as the relative proportions of radioactivity in organs from L-18A-injected animals would be greatly reduced compared with those in r>18A-injected animals; thus, data in Table 5 exclude thyroid radioactivity.
In both peptides, the majority of nonthyroid radioactivity was recovered in the liver and kidney. Although there was no difference in the percent nonthyroid recovered radioactivity in the liver between the two peptides, the percentage of recovered nonthyroid radioactivity in the kidney of r>18A-injected animals was approximately twice that in L-18A-injected animals.
Discussion
Peptide analogues have been designed that mimic native class A amphipathic helixes from exchangeable apolipoproteins in charge distribution, ability to activate lecithin: cholesterol acyltransferase, and ability to associate with lipoproteins. The apolipoprotein-like properties of these peptide analogues can be altered by changing the length of the peptides, the charge distribution, or specific amino acids in the peptide. In the present study, a number of peptide analogues were studied in vivo to determine how the analogues compare with native apo A-I in terms of association with plasma lipoproteins and clearance from plasma.
Clearance curves of apo A-I and synthetic amphipathic peptides fitted best to biexponential equations, with an initial rapid phase and a prolonged slow phase of clearance. No obvious correlation existed between the rapid clearance rate and lipid affinity. This component varied with the individual apolipoprotein or peptide preparations and may have been due to rapid clearance of aggregated, chemically altered, or nonlipoprotein-associated protein or peptides. However, the amount of free peptide present did not appear to correlate with the rapid component of clearance (Tables  3 and 4 ). The rate of the slow component of clearance of synthetic amphipathic peptides from blood in rats was inversely correlated with both their lipid affinities (Table 2) and percent a-helicity (Table 1) . Analogue 37pA, the most surface-active peptide, had the slowest rate of turnover and was comparable with apo A-I, whereas analogue 18R had the fastest clearance rate. The percentage of peptide associated with HDL compared with free peptide also reflected relative lipid affinity. Although all of the analogues associated with HDL, a significant amount of analogue remained in the free protein portion of the plasma in the 18-amino acid peptide analogues, especially 18R (Table 4 ). The faster clearance of these peptides may have been due to equilibration of peptide between the HDL and the free peptide pool, with rapid removal of the free peptide.
The amino acid sequence of apo A-I from rats is strikingly different from human apo A-I in some por- tions of the molecule, especially in the putative 22-mer amphipathic helix-containing regions of residues 150-250; however, the hydrophobic moment plots of the two molecules are similar. 22 Turnover of peptide analogues was compared with the turnover of human ently than the native molecule. No significant differences were observed in the turnover of these three apo A-I species in rats, again suggesting that relative lipid affinity appears to have a greater effect on apo A-I clearance than do simply changes in the amino acid sequence or method of labeling.
The relation between lipid affinity and turnover of peptide analogues described here is similar to that previously reported for phosphatidylcholines, 24 ether analogues of phosphatidylcholines, 24 or lipid-associating peptides (LAPs), 25 although turnover rates of the more hydrophobic LAPs were closer to that of apo A-I than were the turnover rates of the lipids, which were considerably faster. The peptide analogues used in the present study derive their lipid affinity from the distribution of amino acids along the amphipathic helix in the same way that apolipoproteins do. This is in contrast with the LAP of Ponsin et al, 25 in which the radial distribution of amino acids is quite unlike the distribution in class A amphipathic helixes and in which lipid affinity is largely derived from the presence of an acyl chain. However, the association between lipid affinity and turnover rate is quite similar in both the peptide analogues and the LAP, with comparable half-times of clearance. 25 Amphipathic peptide analogues made from D-amino acids would be expected to be resistant to proteolytic degradation, having perhaps a longer residence time in the blood. However, the D-18A peptide analogue, which has a lipid affinity identical to that of the L-18A peptide analogue and was associated with HDL to a similar degree, had a rate of clearance that was not significantly different than that of the L-18A peptide analogue. The facts that free 125 I did not appear in the plasma with time and was not present in the urine suggest that D-18A was not proteolyzed. Thus, it is likely that the D-peptide analogue was taken up by some tissue and stored. Further in vivo studies are required to determine the fate of the D-peptide analogue.
Analysis of the distribution of radioactivity in the urine suggests that excretion in the urine is not an important mechanism of clearance of apolipoproteins from HDL. In rats injected with 125 I-apo A-I or L-18A, radioactivity in the urine was present only as free 125 I; in rats injected with 1 2 5 I-D-18A, the radioactivity was present only as intact peptide (and was much less than that found with L-18A). However, in rats injected with H C-apo A-I, essentially no radioactivity was found in the urine. Free 125 I in blood and urine was presumed to result from hydrolysis of the protein or peptide to amino acids, followed by deiodination. 26 Because 125 I-D-18A is not hydroryzed, no deiodination can occur. Thus, loss of intact apo A-I or peptide in the urine (except possibly in the case of D-18A) does not appear to be a major route of clearance.
The urine radioactivity data do not eliminate the possibility that kidney cells are taking up and storing or degrading the peptides or apo A-I. 25 - 27 Together with those data, the tissue distribution data presented in Table 5 suggest that considerable proportions of the Land D-18A peptides are taken up by the kidney but are not then directly excreted in the urine. This is consistent with the findings by Ponsin et al that suggest that the kidney is a significant target for LAP uptake, especially in LAPs with low-to-moderate lipid association. 25 Three-day tissue distributions were done to ensure that background contamination due to blood was minimized. However, this resulted in relatively low levels of radioactivity remaining in L-18A-injected animals. The majority of the radioactivity present in these animals was found in the thyroid gland, reflecting proteolysis and deiodination, with subsequent uptake of the free iodine by the thyroid gland or excretion through the urine. In addition, differential proteolysis between organs may affect the proportion of radioactivity remaining in those organs. Such proteolysis would not occur in D-peptideinjected animals, as demonstrated by the higher total recovery of radioactivity and very low proportion of radioactivity in the thyroid gland; thus, tissue distribution of the remaining radioactivity may more accurately reflect uptake of peptide by the organs, if one assumes that redistribution of the peptide between organs does not occur.
The speculative model we are proposing for clearance of these peptide analogues is as follows. Peptides with high lipid affinity associate with HDL and are cleared from the plasma with HDL particles by as-yet-unknown mechanisms. Peptides with lower lipid affinity partition between HDL and the plasma free-peptide pool, with the partition coefficient being dependent on lipid affinity. These lower-affinity peptides are cleared more rapidly from the free peptide pool, perhaps by macrophages or other reticuloendothelial tissues, the liver, or the kidneys. They are then proteotyzed and deiodinated except in the case of the D-amino acid peptide analogue, which is stored intact in the cells. The free l2^ is excreted through the urine or is taken up by the thyroid gland.
Association of apo A-I or peptide analogues with cell membranes has been shown to induce biological effects. 28 " 30 We further speculate that such association with cell membranes may be an additional component in the clearance of these peptides.
In summary, peptide analogues of the apolipoprotein-class amphipathic helix appear to be effective tools in studying the metabolism of HDL in vivo. Properties of these peptides will make them useful in further studies of the metabolic fate of HDL and potentially the interrelation among HDL subspecies.
